c*********7
发帖数: 19373 | | y*****l
发帖数: 5997 | | b*****h
发帖数: 783 | 3 SPPI的重头产品Apaziquone的三期结果要2012年才出来，
sppi 目前有两个药在卖，目前的revenue还不大，不过正处于增长的趋势，能增加到多
少不太清楚。
FDA 2009年批准了ZEVALIN的扩展用途，这个会在后面的sale中体现出来，
FUSILEV的sNDA FDA会在2011年四月底给结果，如果批准，那也会增加FUSILEV的sale,
sppi目前应该风险不大，增长点主要来自这两个药的revenue，但这个需要时间。
【在 y*****l 的大作中提到】
: 生物鱼们说说年底有什么炒点？
| y*****l
发帖数: 5997 | 4 马克，多谢，不感兴趣了。
【在 b*****h 的大作中提到】
: SPPI的重头产品Apaziquone的三期结果要2012年才出来，
: sppi 目前有两个药在卖，目前的revenue还不大，不过正处于增长的趋势，能增加到多
: 少不太清楚。
: FDA 2009年批准了ZEVALIN的扩展用途，这个会在后面的sale中体现出来，
: FUSILEV的sNDA FDA会在2011年四月底给结果，如果批准，那也会增加FUSILEV的sale,
: sppi目前应该风险不大，增长点主要来自这两个药的revenue，但这个需要时间。
| y*****l
发帖数: 5997 | 5 下周可能有戏 December 4-7
Spectrum Pharmaceuticals Announces Presentation of Four Key Belinostat
Abstracts at the 52nd Annual Meeting of the American Society of Hematology (
ASH) in Orlando, Florida on December 4-7, 2010
Thursday 11/18/2010 7:00 AM ET - Businesswire
Related Companies
Symbol Last %Chg
SPPI 4.45 -2.84%
As of 4:00 PM ET 11/30/10
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a biotechnology company
with fully integrated commercial and drug development operations with a
primary focus in oncology, today announced four key belinostat data
presentations at the 52nd Annual Meeting of the American Society of
Hematology (ASH), being held at the Orange County Convention Center in
Orlando, Florida, December 4-7, 2010.
For more information about the ASH annual meeting and for a complete list of
abstracts, please refer to the conference Web site at www.hematology.org.
The following are the key belinostat-related abstracts being presented at
the conference:
Date/Time Abstract # Presentation Type/Location
Title
Authors | y*****l
发帖数: 5997 | 6 Spectrum Pharmaceuticals Ranked One of the Fastest Growing Companies in
North America on Deloitte's 2010 Technology Fast 500(TM)
Friday 11/12/2010 7:00 AM ET - Businesswire
Related Companies
Symbol Last %Chg
SPPI 4.45 -2.84%
As of 4:00 PM ET 11/30/10
Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a primary
focus in oncology, today announced that it ranked #23 on Technology Fast 500
(TM), Deloitte's ranking of 500 of the fastest growing technology, media,
telecommunications, life sciences and clean technology companies in North
America. Rankings are based on percentage of fiscal year revenue growing
during the period from 2005-2009. Spectrum Pharmaceuticals grew 6,490%
during this period.
"We are pleased to once again be ranked one of the fastest growing companies
in North America," said Rajesh C. Shrotriya, MD, Chairman of the Board of
Directors, Chief Executive Officer, and President of Spectrum
Pharmaceuticals. "We believe that product revenues from ZEVALIN and FUSILEV
will continue to be strong, and would expect to remain on the Deloitte
Technology Fast 500(TM) list of growing companies in North America for the
next several years."
"Spectrum Pharmaceuticals and the other 2010 Technology Fast 500(TM) winners
forged ahead in a challenging economic environment to realize exceptional
growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology,
media and telecommunications leader. "Deloitte commends Spectrum for this
impressive accomplishment."
Overall, Technology Fast 500(TM) award winners for 2010 had revenue growth
ranging from 146 percent to 164,079 percent from 2005 to 2009, with an
average growth of 2,361 percent.
For additional detail on the Technology Fast 500(TM) including selection and
qualifying criteria, visit www.fast500.com. | y*****l
发帖数: 5997 | 7 Latest News Headlines for Spectrum Pharmaceuticals Incorporated
Spectrum Pharmaceuticals Board Approves Replacement of Stockholder Rights
Agreement
Tuesday 11/30/2010 7:00 AM ET - Businesswire
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI) announced today that on
November 29, 2010 its Board of Directors met with its legal and financial
advisors to consider Spectrum Pharmaceuticals' current stockholder rights
agreement, which originally was adopted in 2000 and is scheduled to expire
on December 13, 2010. At the meeting, the Board voted unanimously to approve
Spectrum Pharmaceuticals' entry into a replacement rights agreement that
will extend until December 13, 2020 the framework of the current rights plan
. A stockholder rights agreement is designed to deter coercive, unfair, or
inadequate takeovers and other abusive tactics that might be used in an
attempt to gain control of Spectrum Pharmaceuticals without paying all
stockholders a fair price for their shares. A stockholder rights agreement
will not prevent takeovers at a full and fair price, but rather is designed
to deter coercive takeover tactics and to encourage anyone attempting to
acquire Spectrum Pharmaceuticals to first negotiate with the Board of
Directors.
Spectrum Pharmaceuticals Bd Approves Replacement Of Stockholder Rights
Agreement
Tuesday 11/30/2010 7:00 AM ET - Dow Jones News
Spectrum Pharma Says FDA PDUFA Action Date Is April 29, 2011
Monday 11/29/2010 7:09 AM ET - Dow Jones News
Spectrum Pharma Says FDA Accepts Fusilev SNDA For Filing,Review
Monday 11/29/2010 7:08 AM ET - Dow Jones News
FDA Accepts For Review Spectrum's Response On FUSILEV(R) As A Class 2
Submission, And Establishes April 29, 2011 As PDUFA Action Date >SPPI
Monday 11/29/2010 7:00 AM ET - Dow Jones News
FDA Accepts for Review Spectrum's Response on FUSILEV(R) as a Class 2
Submission, and Establishes April 29, 2011 as PDUFA Action Date
Monday 11/29/2010 7:00 AM ET - Businesswire | s*********m
发帖数: 2043 | 8 哈哈
版上一年前的老相好啊
【在 c*********7 的大作中提到】
: 感觉要有动作。
| c*********7
发帖数: 19373 | 9 主要是觉得最近庄家吸货明显，而且消息逐渐多起来，似乎改有所动作。而且应该是不
小，可能先回到5，然后波折几次到6.看消息的程度了。 | y*****l
发帖数: 5997 | 10 估计有戏，你在首贴说得太简单了。
【在 c*********7 的大作中提到】
: 主要是觉得最近庄家吸货明显，而且消息逐渐多起来，似乎改有所动作。而且应该是不
: 小，可能先回到5，然后波折几次到6.看消息的程度了。
| | | c*********7
发帖数: 19373 | 11 其实它很像前一阵的AVII。新低然后徘徊，上升地点，打下来，然后一个上升通道将近
1个月。 | c*********7
发帖数: 19373 | | f**********g
发帖数: 2252 | 13 up
【在 c*********7 的大作中提到】
: 感觉要有动作。
| f**********g
发帖数: 2252 | 14 FDA Accepts for Review Spectrum's Response on Fusilev as a Class 2
Submission
Thursday 12/02/2010 1:25 AM ET - Close-up Media
Related Companies
Symbol Last %Chg
SPPI 4.85 2.54%
As of 11:43 AM ET 12/3/10
Spectrum Pharmaceuticals, a biotechnology company with fully integrated
commercial and drug development operations with a primary focus in oncology,
announced that the U.S. Food and Drug Administration (FDA) has accepted for
filing and review the complete response regarding its supplemental New Drug
Application (sNDA) for Fusilev (levoleucovorin) for Injection for treatment
of patients with advanced metastatic colorectal cancer.
The FDA considers the submission a Class 2 response, therefore, the PDUFA
Action Date is April 29, 2011, according to the Company.
Fusilev is currently FDA approved and marketed by Spectrum for rescue after
high-dose methotrexate therapy in osteosarcoma. Fusilev is also indicated to
diminish the toxicity and counteract the effects of impaired methotrexate
elimination, and of inadvertent overdosage of folic acid antagonists.
Fusilev, a novel folate analog, is available in vials as freeze-dried powder
. Fusilev rescue is indicated after high-dose methotrexate therapy in
osteosarcoma. Fusilev is also indicated to diminish the toxicity and
counteract the effects of impaired methotrexate elimination and of
inadvertent overdosage of folic acid antagonists. Fusilev has been marketed
outside the United States by Wyeth, Sanofi-Aventis, Takeda, and others for
more than 10 years.
Spectrum Pharmaceuticals is a biotechnology company with fully integrated
commercial and drug development operations with a primary focus in oncology.
The Company's strategy is comprised of acquiring, developing and
commercializing a broad and diverse pipeline of late-stage clinical and
commercial products.
More information:
sppirx.com
((Comments on this story may be sent to n******[email protected])) | c*********7
发帖数: 19373 | 15 sppi走的很不错，现在还没出量。估计有个消息就大爆发了。 | f**********g
发帖数: 2252 | 16 Conf tommorow. December 4-7
发信人: yaokarl (大象), 信区: pennystock
标 题: Re: 推荐sppi
发信站: BBS 未名空间站 (Tue Nov 30 21:51:22 2010, 美东)
下周可能有戏 December 4-7
Spectrum Pharmaceuticals Announces Presentation of Four Key Belinostat
Abstracts at the 52nd Annual Meeting of the American Society of Hematology (
ASH) in Orlando, Florida on December 4-7, 2010
【在 c*********7 的大作中提到】
: sppi走的很不错，现在还没出量。估计有个消息就大爆发了。
| c*********7
发帖数: 19373 | 17 我个人定义了个皮球理论。如果一只股没有坏消息，基本层面不错的话。如果近期被打
压到一个52周的低点，那么反弹的时候就会超过52周的高点。所以我觉得sppi超过5.5
没有问题。 | d******l
发帖数: 1145 | | c*********7
发帖数: 19373 | 19 看来sppi还是很有前途的，据说有大机构想收购。 | M*******a
发帖数: 870 | 20 still holding
5
【在 c*********7 的大作中提到】
: 我个人定义了个皮球理论。如果一只股没有坏消息，基本层面不错的话。如果近期被打
: 压到一个52周的低点，那么反弹的时候就会超过52周的高点。所以我觉得sppi超过5.5
: 没有问题。
| | | x****7
发帖数: 895 | | c*********7
发帖数: 19373 | | b**********k
发帖数: 1262 | 23 NB...
【在 c*********7 的大作中提到】
: 哈哈，正式勃起。
| d******d
发帖数: 1037 | | x*****g
发帖数: 516 | | c*********7
发帖数: 19373 | 26 今天走的这么牛难带就是个把没正经的消息？我的皮球理论竟然这么快就兑现了。 | M*******a
发帖数: 870 | 27 打算啥时候卖？盘后都快6块了。。。
【在 c*********7 的大作中提到】
: 今天走的这么牛难带就是个把没正经的消息？我的皮球理论竟然这么快就兑现了。
| c*********7
发帖数: 19373 | 28 按我的皮球理论的话，反弹应该到6.02。
【在 M*******a 的大作中提到】
: 打算啥时候卖？盘后都快6块了。。。
| M*******a
发帖数: 870 | 29 6.02快到啦，你设了6.02的卖单？
【在 c*********7 的大作中提到】
: 按我的皮球理论的话，反弹应该到6.02。
| y*****e
发帖数: 1449 | | | | M*******a
发帖数: 870 | 31 这是要收购了吗？消息不出来俺不打算卖
【在 y*****e 的大作中提到】
: 盘后太猛了！
: 卖了算了？
| j******g
发帖数: 1098 | 32 已经过了6.02了
【在 M*******a 的大作中提到】
: 6.02快到啦，你设了6.02的卖单？
| M*******a
发帖数: 870 | 33 都怪那个烂bac,占了俺大把资金，前两周sppi加的太少。。。
【在 j******g 的大作中提到】
: 已经过了6.02了
| j******g
发帖数: 1098 | | p********e
发帖数: 1960 | 35 ft...only have 600 shares.....
【在 M*******a 的大作中提到】
: 都怪那个烂bac,占了俺大把资金，前两周sppi加的太少。。。
| c*********7
发帖数: 19373 | 36 我用sogo盘后没法交易。呵呵。而且盘后量太少了，还是明天开盘看情况吧，这波来的
太猛太快，不过庄家的确把sppi的筹码吸足了，前几天几千股就能随意波动5%，不出个
3M庄家不甘心呀。 | g******d
发帖数: 511 | 37 $4.1x买了不少，捂了不少时间．终于等到了． | y*****l
发帖数: 5997 | 38 Spectrum's Zevalin shows positive results in study
Spectrum Pharmaceuticals' Zevalin shows positive results in midstage cancer
study
Related Quotes
Symbol Price Change
SPPI 5.41 +0.46
Chart for Spectrum Pharmaceuticals, Inc.
{"s" : "sppi","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","
j" : ""}
On Monday December 6, 2010, 5:27 pm EST
IRVINE, Calif. (AP) -- Spectrum Pharmaceuticals Inc. said Monday its drug
Zevalin showed positive results in a midstage study focusing on a type of
cancer called follicular lymphoma.
Follicular lymphoma is the most common type of non-Hodgkin's lymphoma, which
is a cancer affecting the lymph system. Zevalin is already approved for
types of non-Hodgkin's lymphoma.
The current midstage study focuses on using Zevalin as a standalone
treatment for patients who have not received prior therapy. The results come
from independent researchers from leading universities in Germany, Austria,
Italy, and Sweden, the company said.
The data were presented at the American Society of Hematology's annual
meeting in Orlando, Fla.
Preliminary results from the 60-patient study show that patients who
received a single dose of the drug had a one-year overall clinical response
rate of 84 percent. The response is similar to other results reported in
previous studies of the drug, the company said.
Shares of Spectrum rose 28 cents to $5.69 in after-hours trading after
jumping 46 cents, or 9.3 percent, to close at $5.41 during the regular
trading session.
【在 c*********7 的大作中提到】
: 今天走的这么牛难带就是个把没正经的消息？我的皮球理论竟然这么快就兑现了。
| y*****l
发帖数: 5997 | 39 UPDATE 1-Spectrum Pharma says cancer drug shows promise; shrs up
SPECTRUM PHARMACEUTICALS, INC.
SPPI.O
$5.41
+0.46+9.29%
2:00pm CST
Mon Dec 6, 2010 5:51pm EST
* Mid-stage trial sees 84 pct response rate
* Late-stage study shows 35 months progression-free survival
* Shares up 10 pct
Dec 6 (Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said a mid-stage
trial of its injection for non-Hodgkin's lymphoma (NHL), a type of cancer,
as a first-line therapy showed positive results, sending its shares up 10
percent.
Patients who were given a single dose of the drug Zevalin without upfront
chemotherapy showed a response rate of 84 percent, the company said.
Spectrum also said a late-stage trial of the drug showed nearly three years
of progression-free survival benefit in patients with NHL after partial or
complete response to first-line chemotherapy.
The company said it plans to submit the data for consideration to the U.S.
Food and Drug Administration to remove the bioscan requirement before taking
the injection.
Spectrum shares, which have risen 18 percent since the U.S. FDA accepted its
cancer drug for review in November, were up 10 percent at $5.96 in extended
trade on Monday. (Reporting by Shravya Jain in Bangalore; Editing by Vinu
Pilakkott) | q********g
发帖数: 10694 | | | | c*********7
发帖数: 19373 | 41 最好别跟，我刚出了一半。建议上C，这个还是有前途。
【在 q********g 的大作中提到】
: 还有机会么？
| N*S
发帖数: 213 | |
|
